P542: Long-term outcomes after switching from originator infliximab to biosimilar in paediatric-onset inflammatory bowel disease patients: a single centre prospective observational studyECCO '17 Barcelona
2017
P543: Structured transition enhances clinical outcome without an increase in healthcare cost in adolescent patients with IBD: the UK TRANSIT studyECCO '17 Barcelona
2017
P544: Combination therapy of vedolizumab and a TNF antagonist in IBD patients with severe chronic active, therapy refractory disease courseECCO '17 Barcelona
2017
P545: Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients in clinical remission: preliminary resultsECCO '17 Barcelona
2017
P546: Which are the optimal adalimumab trough levels associated with biological remission in patients with inflammatory bowel disease?ECCO '17 Barcelona
2017
P548: Hepatitis B virus reactivation in hepatitis B virus infected patients with inflammatory bowel disease receiving anti-tumor necrosis factor-alpha therapyECCO '17 Barcelona
2017
P549: Effect of maintenance Ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's diseaseECCO '17 Barcelona
2017
P552: An online educational portal improves concerns of inflammatory bowel disease patients regarding pregnancy and medicationECCO '17 Barcelona
2017
P553: Long-term outcomes of seton drainage for perianal fistulizing Crohn's diseaseECCO '17 Barcelona
2017
P554: Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trialECCO '17 Barcelona
2017
P555: Systematic review of interventions for chronic abdominal pain management in inflammatory bowel diseaseECCO '17 Barcelona
2017
P556: Female Crohn's disease patients and ulcerative colitis patients on biologic therapy are most disabledECCO '17 Barcelona
2017
P557: Utility of “trough levels” adalimumab determination in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters through population pharmacokinetic modelECCO '17 Barcelona
2017
P558: The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitisECCO '17 Barcelona
2017
P560: Trough levels at induction: impact on long term response when re-initiating infliximabECCO '17 Barcelona
2017